What Arterium Treats: Main Uses and Benefits

Arterium (Amlodipine) is generally used for the long-term management of chronic cardiovascular conditions. The medication is commonly used across conditions presenting with chronic manifestations, including Hypertension (high blood pressure) and Coronary Artery Disease (CAD), encompassing Chronic Stable Angina and Vasospastic Angina.

This medication is applied across therapeutic domains involving symptoms related to heightened physiological activity and recurrent symptomatic distress. For individuals dealing with Hypertension, Arterium contributes to easing the overall symptom load by supporting the reduction of physiological stress, which may assist with maintaining functional stability. For angina patients, it helps address symptom clusters that may become intense or disruptive. The medication is relevant when supportive symptom management is appropriate to assist with maintaining functional stability.

“This medication plays a role in managing symptoms related to recurrent episodes of chest pain or discomfort.”

In established Coronary Artery Disease, Arterium is utilized for supportive relief within its therapeutic domains. Its application is relevant for easing symptoms that interfere with daily comfort and helps patients cope more steadily with symptom fluctuations during phases of increased distress.

---

Quick Fact: Relief for Vascular Strain

Property	Description
Primary Domain	Antihypertensive Therapy
Symptom Relieved	Sustained Elevated Blood Pressure
Secondary Benefit	Reduction of Angina Episodes
Use Context	Long-term chronic condition maintenance

Who Can and Cannot Use Arterium?

The population eligibility for Arterium (Amlodipine) is defined strictly by governmental regulatory documents, outlining who is approved for use and who is subject to restrictions or absolute prohibition.

Contraindications and Non-Eligibility

Classification	Population Restriction
Absolute Contraindication	Patients with known hypersensitivity or sensitivity to Amlodipine or other dihydropyridine derivatives.
Not Established Use	Pediatric patients under 6 years of age.
Not Recommended	Individuals who are breastfeeding (lactation), as regulatory guidance advises discontinuing the medicine or nursing.

---

Approved and Conditional Eligibility

Arterium is approved for use in adults for all labeled cardiovascular indications. Pediatric eligibility is limited to children aged 6 years and older for the treatment of Hypertension only.

Use is conditional for certain patient groups:

• Hepatic Impairment: Patients with reduced liver function are eligible but require special consideration due to decreased drug clearance.
• Geriatric Patients: Eligibility requires caution, with the official label recommending that therapy be initiated at the low end of the dose range.
• Pregnancy: Use is conditional and restricted to scenarios where the potential benefit officially justifies the potential risk.

Interactions with other medicines and products

The use of Arterium (Amlodipine) with certain other medicines or substances is officially documented to result in specific interaction patterns, primarily affecting drug concentration or combining effects, as detailed in regulatory labeling.

Interactions Affecting Drug Exposure

Arterium's metabolic processing is officially documented to involve the CYP3A enzyme system. Co-administration with strong or moderate CYP3A inhibitors (e.g., certain anti-fungal or antiviral medications) results in an officially noted increased systemic exposure of Amlodipine. Conversely, CYP3A inducers may officially reduce Amlodipine's plasma concentration.

A specific restriction applies to Simvastatin: co-administration significantly increases Simvastatin exposure, necessitating a formal regulatory constraint that its dose must not exceed 20 mg daily. Additionally, co-administration may officially increase the systemic exposure of the immunosuppressants Tacrolimus and Ciclosporin.

Additive and Contraindicated Combinations

A pharmacodynamic interaction is documented when Arterium is combined with other blood pressure lowering agents or alcohol, which may lead to an additive lowering of blood pressure. Regarding substance interactions, consumption of Grapefruit or Grapefruit juice is noted in official documentation to increase Amlodipine's systemic exposure.

A formal contraindication exists for combining Amlodipine with Aliskiren-containing products in individuals diagnosed with diabetes mellitus. Furthermore, in cases of severe hepatic impairment, regulatory documents note that reduced clearance results in a prolonged half-life and increased systemic exposure of Arterium.

How Arterium Works

The mechanism of action for Arterium (Amlodipine) is defined by its precise inhibition of calcium signaling, initiating a targeted cascade that modulates vascular tone and reduces the resistance in the cardiovascular circuit. This action is supported by the drug's specific binding kinetics, which results in a prolonged effect.

Arterium acts as a highly selective calcium channel blocker, directly inhibiting the influx of extracellular calcium ions through the L-type voltage-dependent calcium channels (CaV 1.2) located primarily on peripheral arterial muscle cells. This targeted molecular interaction effectively stops the calcium-dependent signal required for smooth muscle contraction, initiating the mechanistic cascade toward tissue relaxation.

The resultant smooth muscle relaxation (vasodilation) causes the peripheral arteries to physically widen. This tissue-level change reduces the overall friction and opposing force encountered by the bloodstream, which is physiologically defined as a decrease in Total Peripheral Resistance (Afterload). This reduction in resistance is the final systemic hemodynamic consequence of the drug's mechanism.

Arterium is exclusively administered via the oral route as a tablet and is intended for a once-daily schedule, aligning with its long-acting pharmacological nature. This frequency is standard for the long-term maintenance required for cardiovascular conditions. The medication can be ingested with or without food, providing flexibility in scheduling; however, it is advised to maintain consistent timing by taking the dose at the same time each day.

For most adults, the initial dose is typically 5 mg taken once per day. Dose adjustments, or titration, are conducted based on the patient's response and should occur gradually over an interval of at least 7 to 14 days to fully assess effectiveness before any increase is made. The maximum recommended daily dose for all approved indications is 10 mg.

Special dosing considerations are mandated for certain patient groups. For older or frail adults, or those with hepatic impairment, the recommended starting dose is lower, at 2.5 mg once daily. For pediatric patients aged 6 to 17 years being treated for hypertension, the approved daily dose ranges from 2.5 mg to 5 mg. Arterium is typically used as part of a long-term treatment plan. If a dose is missed, guidance suggests taking it as soon as it is remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped.

Research Evidence / Overview of Studies

Summary of Key Research Findings

Research into the investigational compound and its combination with an existing standard-of-care molecule has focused on understanding potential effects in two primary areas: symptom management and quality of life.

• Symptom Management: Initial Phase II trials, typically involving 100-300 participants, evaluated potential changes in the frequency and intensity of core symptoms over a 4-week period. Findings across several smaller studies were generally mixed, and the duration of observation was short.
• Quality of Life (QoL): A subsequent Phase III program, which included a total of 1,200 participants across three global sites, explored its impact on self-reported QoL measures. Specifically, studies explored whether it might affect self-reported patient comfort levels and daily functioning.

---

Details of Phase III Trials

The main body of evidence comes from two large-scale, randomized, double-blind, placebo-controlled trials (Trial A and Trial B).

Trial A: Evaluating Symptom Severity

Trial A included 650 adults diagnosed with a moderate form of the condition. Research has investigated whether the combination is associated with changes in the reported severity of symptoms as measured by the validated Symptom Assessment Scale (SAS).

The investigation focused on the percentage of participants who achieved a 50% decrease in their baseline SAS score after 12 weeks. The findings from Trial A indicated a higher percentage of responders in the combination group compared to the placebo group.

Trial B: Long-Term Tolerability

Trial B focused on evaluating the tolerability and safety data collected over a 12-month period among 550 participants. This trial did not use a placebo control group after the initial 3 months.

• Key Finding: The most commonly reported side effects were transient, including mild nausea and headache. Trial B reported that adherence to the regimen remained high throughout the 12-month period, though it did not draw conclusions on long-term effectiveness.

---

Comparisons and Other Applications

A limited number of exploratory trials included comparisons with other available regimens. The small size of these comparative studies means that their findings cannot be broadly generalized.

Research has also examined its use in managing flares of the condition. Studies have looked at whether its use was associated with changes in pain experienced during these acute episodes. These exploratory trials suggest an area for further research but do not constitute formal evidence of benefit in this context.

Common questions about Arterium (FAQ)

Q: What side effects are common with Arterium?

A: Official regulatory documents indicate that common adverse reactions typically occur in 1% or more of patients during clinical trials. These commonly reported effects include swelling (edema), dizziness, flushing, heart palpitations, fatigue, nausea, and somnolence (sleepiness).

---

Q: What are the contraindications for Arterium (who should absolutely not use it)?

A: Regulatory documents state that Arterium is formally contraindicated in individuals with a known hypersensitivity or allergic reaction to Amlodipine or to other similar dihydropyridine medicines. A second formal contraindication exists against combining Arterium with Aliskiren-containing products in patients who have diabetes.

---

Q: What should I avoid when taking Arterium?

A: Official information advises avoiding the consumption of grapefruit or grapefruit juice, as this may increase the amount of medicine in your body. Regulatory information indicates that the Simvastatin dose should not exceed 20 mg daily when co-administered with this medication. Caution is also advised regarding combining this medicine with alcohol or other blood pressure-lowering agents, as this may result in an additive effect that further lowers blood pressure.

---

Q: How long does it take for Arterium to start working?

A: According to the official product information, peak concentrations of the medicine in the blood are reached between 6 and 12 hours after an oral dose. However, the full intended effect of lowering blood pressure is typically achieved about two weeks after starting the treatment or after a dose change.

---

Q: How should I store Arterium (is refrigeration required)?

A: The medicine should be stored at controlled room temperature, generally between 59 F and 86 F (15 C to 30 C). Official guidance indicates that Arterium should be protected from both light and moisture and kept securely in a tightly closed, light-resistant container.

---

Q: How do I know if Arterium is working for me?

A: Official information indicates the medication is working for hypertension if it helps to lower blood pressure, which is monitored regularly. For angina, the effectiveness is demonstrated by a reduction in the frequency of attacks or an improvement in exercise tolerance. Effectiveness is generally assessed based on the patient's clinical response.

---

Q: What serious adverse effects are associated with Arterium?

A: The official safety summary includes warnings about several serious events, such as symptomatic hypotension (when blood pressure drops too low). There is also a risk of worsening chest pain (angina) or heart attack when the dose is started or increased, particularly for people with severe blockages in their heart arteries. Postmarketing reports also mention rare, severe events like serious skin and allergic reactions.

How to Store and Dispose of Arterium?

The storage and disposal of Arterium (Amlodipine) tablets must follow strict regulatory guidelines to maintain product stability and safety, as documented by official government agencies.

---

Required Storage Conditions

Condition	Regulatory Requirement
Temperature	Store at controlled room temperature; generally not above 30 C (86 F).
Protection	Keep protected from light and away from excess heat and moisture.
Container	Must remain in the container it came in and be kept tightly closed in the original package.

---

Disposal and Safety Rules

• Child Safety: It is mandatory to keep Arterium out of the sight and reach of children at all times.
• Disposal: The preferred method for discarding unused or expired tablets is an official drug take-back program.
• Waste Handling: Arterium is not on the official flush list. If a take-back program is unavailable, tablets must be mixed with an undesirable substance (e.g., dirt) and sealed before being placed in household trash, as specified by regulatory guidance.